IndieBio is an accelerator firm established in 2014 and based in San Francisco, California, with an additional office in New York. It specializes in startups that utilize synthetic biology to address significant global challenges. IndieBio runs four-month accelerator programs aimed at both companies and teams with innovative ideas, focusing on seed-stage and early-stage investments. The firm typically invests $250,000, providing $50,000 in exchange for eight percent equity in biotech startups, with the possibility of an additional $25,000 as a convertible loan note. IndieBio prioritizes investments in businesses that leverage biology as the core of their technology, particularly in life sciences, biotechnology, and related fields. The firm favors teams with a minimum of two co-founders and is open to investing in startups from various geographical locations.
AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.
Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.
Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.
PluriCell wants to positively impact the lives of millions of patients suffering from chronic heart failure condition by injecting healthy bona fide lab-made human heart cells in their failing heart, improve its function and, ultimately, the clinical outcome of the patients. Our tech enables us not only tackle heart diseases, but potentially, many chronic disorders currenly untractable.
Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.
Cellens is a spinoff company from Tufts University focused on enhancing cancer screening through noninvasive methods. The company has developed a cell surface scanning platform aimed at assisting oncologists in the detection of bladder cancer. Utilizing atomic force microscopy imaging combined with machine learning, Cellens' technology analyzes physio-biomarkers on cell surfaces derived from urine samples. This innovative approach generates a diagnostics score for bladder cancer, enabling healthcare providers, including oncologists and urologists, to minimize the need for invasive and costly diagnostic procedures. By improving the accuracy of bladder cancer detection, Cellens aims to optimize the patient experience and increase survival rates.
OncoPrecision
Seed Round in 2021
We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.
Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.
Rizlab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing practitioners and patients with rapid blood count readings, specifically focusing on white blood cell analysis. Rizlab Health's electronic cytometer and analyzer utilize a cartridge system to quantify key cellular components, such as neutrophils and lymphocytes. This technology enables hospitals and healthcare providers to quickly and affordably monitor patients' white blood counts, which is crucial for diagnosing conditions like sepsis and distinguishing between bacterial and viral infections. By offering a fast, portable, and cost-effective health monitoring solution, Rizlab Health aims to enhance patient care and streamline clinical decision-making processes.
Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.
Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.
JointechLabs, Inc. is a company focused on enhancing access to cell-based therapies for healthcare providers and patients. Based in Mount Prospect, Illinois, the company has developed the Mini-Stem System, a closed disposable kit designed for the processing and extraction of stromal vascular cell fractions from human tissue. This innovative medical device allows for the efficient preparation of high-quality injectable fat grafts and fat-derived stem cells, facilitating on-site access to optimized adipose-derived stromal cells (ADSC). By streamlining the process of individualized cell and tissue-based therapies, JointechLabs aims to make these advanced treatments more accessible and cost-effective for use in hospitals, clinics, and local medical offices. Since its incorporation in 2012, the company has been dedicated to improving the efficacy and availability of cell therapies in clinical settings.
Chronus Health, Inc. is focused on developing a portable diagnostic platform that delivers rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide real-time diagnoses within minutes. This handheld device significantly enhances the ability of healthcare providers to access actionable data on-site, thereby improving patient outcomes and reducing the time to care. Chronus Health aims to transform the diagnostic process by enabling immediate treatment decisions based on accurate lab results.
OncoPrecision
Convertible Note in 2021
We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.
OncoPrecision
Pre Seed Round in 2021
We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.
Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.
EMBER Medical is a telehealth platform that facilitates immediate connections between patients and medical professionals, including physicians, nurses, and EMTs, within a five-minute walking distance. Founded in 2018 and based in San Francisco, California, EMBER Medical's mobile application provides users with the ability to engage in private audio and video consultations, ensuring timely medical assistance. The platform is designed to enhance healthcare accessibility, particularly in underserved regions, by enabling patients to receive quality remote care and allowing medical professionals to utilize a comprehensive suite of virtual clinic tools. EMBER Medical aims to streamline the healthcare experience by connecting individuals to the right care quickly and efficiently, promoting a more personalized approach to health management.
Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Sequential Skin is a diagnostic platform company targeting skin longevity and aging. Our team specialises in genetics, epigenetics, and the skin microbiome.
Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.
BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential.
Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.
Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.
BioFeyn specializes in the development of nanocapsules designed for human medicine and aquaculture. These tiny molecular transporters effectively deliver nutrients, drugs, and natural products, enhancing fish health while minimizing environmental pollution. The company employs a targeted, modular delivery mechanism to ensure that essential nutrients and natural disease preventatives reach fish, thereby promoting the production of sustainable and nutritious farmed fish. BioFeyn's solutions are adaptable across various species and can be seamlessly integrated into existing supply chains, benefiting both human consumers and the planet. The team comprises experts in materials engineering, molecular biology, and medicine, reflecting a multidisciplinary approach to addressing challenges in health and sustainability.
Allied Microbiota, LLC is a biotechnology company focused on developing microbial products and enzymes to address environmental contamination more efficiently and cost-effectively than traditional remediation methods. Originating from technology at Columbia University, the company's flagship product, PacBac, offers a microbial-based solution for the rapid reduction of stubborn soil contaminants, including poly-chlorinated biphenyls (PCBs), achieving up to 80% reduction in just days. This innovative approach presents significant cost savings—up to 80% compared to conventional remediation techniques like incineration—while effectively eliminating contaminants as a liability rather than merely relocating them. In addition to PacBac, Allied Microbiota is engaged in ongoing research and development to identify new microbial strains and create additional bio-products using advanced methodologies in synthetic biology, proteomics, and data science. By focusing on sustainable biochemicals and biological remediation methods, the company aims to transform the soil-remediation industry, which is valued at approximately $20 billion annually.
Aluna is a healthcare company based in San Francisco, California, that specializes in respiratory management solutions for individuals with chronic lung conditions, including asthma, cystic fibrosis, and COPD. The company has developed a portable spirometry test device that is integrated with an interactive iPhone game, creating an engaging way for users to monitor their respiratory health. Aluna's health platform enables users, particularly children and their parents, to track asthma symptoms, manage medication, and monitor treatment progress. Additionally, the platform offers real-time data that can be shared with healthcare providers, facilitating better insights into asthma triggers and events. Founded in 2013, Aluna aims to improve the quality of life for those living with chronic respiratory conditions.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.
BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.
BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.
BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.
Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.
Advanced Microbubbles Inc specializes in the development of microbubbles, which serve as ultrasound contrast agents for targeted drug delivery. Founded in 2020 and based in Newark, California, the company offers a range of products, including size-isolated microbubbles and biotin- or streptavidin-tagged variants. These microbubbles are designed for applications in ultrasound imaging, noninvasive cancer surgery, and enhancing drug delivery across challenging biological barriers, such as the blood-brain barrier. By focusing on precision drug and gene delivery, Advanced Microbubbles aims to improve treatment outcomes and reduce side effects for patients with neurological conditions and cancer.
Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.
Biomage focuses on single-cell analysis to advance life sciences by providing innovative computational methods to derive insights from biological data. The company has developed the Biomage Single Cell Platform, which allows researchers to efficiently analyze single-cell RNA sequencing data. This platform transforms complex datasets into actionable biological insights, facilitating research in both academia and industry. By streamlining the data analysis process, Biomage empowers scientists to enhance drug target discovery while making the application of advanced sequencing technologies more accessible and cost-effective.
CASPR Biotech is a San Francisco-based company established in 2018 that specializes in developing a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. By offering a simple, fast, and affordable solution, CASPR Biotech aims to assist healthcare providers in delivering efficient diagnostics within clinical and hospital settings.
CASPR Biotech is a San Francisco-based company established in 2018 that specializes in developing a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. By offering a simple, fast, and affordable solution, CASPR Biotech aims to assist healthcare providers in delivering efficient diagnostics within clinical and hospital settings.
sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.
Chronus Health, Inc. is focused on developing a portable diagnostic platform that delivers rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide real-time diagnoses within minutes. This handheld device significantly enhances the ability of healthcare providers to access actionable data on-site, thereby improving patient outcomes and reducing the time to care. Chronus Health aims to transform the diagnostic process by enabling immediate treatment decisions based on accurate lab results.
EMBER Medical is a telehealth platform that facilitates immediate connections between patients and medical professionals, including physicians, nurses, and EMTs, within a five-minute walking distance. Founded in 2018 and based in San Francisco, California, EMBER Medical's mobile application provides users with the ability to engage in private audio and video consultations, ensuring timely medical assistance. The platform is designed to enhance healthcare accessibility, particularly in underserved regions, by enabling patients to receive quality remote care and allowing medical professionals to utilize a comprehensive suite of virtual clinic tools. EMBER Medical aims to streamline the healthcare experience by connecting individuals to the right care quickly and efficiently, promoting a more personalized approach to health management.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.
Antibiotic Adjuvant, Inc. develops decision support software aimed at enhancing antibiotic use in healthcare settings. Its primary product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance within healthcare facilities. The software serves various healthcare professionals by equipping administrators with tools and educational resources to optimize antibiotic use, providing physicians with relevant prescribing information, and supplying nurses with surveillance tools for infection reporting and diagnosis. Founded in 2014 and based in Gainesville, Florida, Antibiotic Adjuvant is unique in its approach, targeting 90% of physician hospital antibiotic prescriptions and facilitating automated resistance control to streamline antibiotic usage patterns.
Chronus Health, Inc. is focused on developing a portable diagnostic platform that delivers rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide real-time diagnoses within minutes. This handheld device significantly enhances the ability of healthcare providers to access actionable data on-site, thereby improving patient outcomes and reducing the time to care. Chronus Health aims to transform the diagnostic process by enabling immediate treatment decisions based on accurate lab results.
CASPR Biotech is a San Francisco-based company established in 2018 that specializes in developing a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. By offering a simple, fast, and affordable solution, CASPR Biotech aims to assist healthcare providers in delivering efficient diagnostics within clinical and hospital settings.
BiomeSense is revolutionizing human microbiome research by developing novel technologies to enable investigators to collect, store, and analyze the daily microbiome profiles of clinical trial participants in a low-cost, scalable way. By enabling daily profiling, the platform allows investigators the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, dramatically increasing the research discovery potential.
11 Biomics LLC develops biological therapeutics for the cannabis industry. It offers small and large scale treatment and protection against fungal and bacterial diseases in cannabis and hemp. The company is based in Albuquerque, New Mexico.
NeuroQore, Inc. is a Canadian company based in Ottawa, established in 2012, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating resistant cases of depression. The organization is composed of a dedicated team of scientists, engineers, and clinicians who focus on pioneering neuromodulation treatments for various neurobehavioral conditions. NeuroQore collaborates with leading universities and research clinics to explore innovative solutions for major depressive disorder and suicidality, striving to improve the lives of individuals affected by these serious mental health issues. The company's advanced technology is designed for deployment in healthcare facilities globally.
Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.
AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.
Clinicai Inc. is a technology company that specializes in health monitoring through innovative bathroom diagnostics. Established in 2016 and located in San Francisco, California, Clinicai develops smart toilet monitoring devices equipped with sensor networks and artificial intelligence. These devices are designed to non-invasively track health by analyzing stool and urine, facilitating early detection of gastrointestinal cancers and other diseases. By creating a connected ecosystem of monitoring platforms and embedded health tracking sensors, Clinicai enables individuals to gather important health data within the home environment, allowing for proactive management of potential health risks.
EMBER Medical is a telehealth platform that facilitates immediate connections between patients and medical professionals, including physicians, nurses, and EMTs, within a five-minute walking distance. Founded in 2018 and based in San Francisco, California, EMBER Medical's mobile application provides users with the ability to engage in private audio and video consultations, ensuring timely medical assistance. The platform is designed to enhance healthcare accessibility, particularly in underserved regions, by enabling patients to receive quality remote care and allowing medical professionals to utilize a comprehensive suite of virtual clinic tools. EMBER Medical aims to streamline the healthcare experience by connecting individuals to the right care quickly and efficiently, promoting a more personalized approach to health management.
Chronus Health, Inc. is focused on developing a portable diagnostic platform that delivers rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide real-time diagnoses within minutes. This handheld device significantly enhances the ability of healthcare providers to access actionable data on-site, thereby improving patient outcomes and reducing the time to care. Chronus Health aims to transform the diagnostic process by enabling immediate treatment decisions based on accurate lab results.
Mouth2Mouth is a healthcare startup that develops personalized probiotics for oral health. Based on microbiome data from thousands of healthy individuals, their AI-driven platform determines consortia of beneficial bacteria that fight widespread conditions such as tooth decay, gum disease, and bad breath. The company is on a mission to improve oral hygiene and provide a solution to oral diseases by use of an all-natural process.
Filtricine, Inc. is a clinical-stage biotechnology company based in Santa Clara, California, focused on developing therapeutic products for cancer treatment. Founded in 2017, the company specializes in a novel nutrient modulation platform that targets and depletes essential nutrients critical for cancer cell growth. By exploiting the metabolic vulnerabilities of cancer cells, Filtricine aims to halt the spread of cancer without relying on traditional drug substances. This approach allows healthcare professionals to utilize targeted nutrient deprivation therapy to address a broad spectrum of cancers effectively.
JointechLabs, Inc. is a company focused on enhancing access to cell-based therapies for healthcare providers and patients. Based in Mount Prospect, Illinois, the company has developed the Mini-Stem System, a closed disposable kit designed for the processing and extraction of stromal vascular cell fractions from human tissue. This innovative medical device allows for the efficient preparation of high-quality injectable fat grafts and fat-derived stem cells, facilitating on-site access to optimized adipose-derived stromal cells (ADSC). By streamlining the process of individualized cell and tissue-based therapies, JointechLabs aims to make these advanced treatments more accessible and cost-effective for use in hospitals, clinics, and local medical offices. Since its incorporation in 2012, the company has been dedicated to improving the efficacy and availability of cell therapies in clinical settings.
Vetherapy is a biotechnology company based in San Francisco, California, specializing in veterinary regenerative medicine and tissue engineering. Founded in 2015, the company develops stem cell therapy products for cats, dogs, and horses, aimed at accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy emphasizes quality and safety in its processes, which include the isolation, expansion, and cryopreservation of stem cells, as well as the preparation of platelet-rich plasma. By providing veterinarians with access to a stem cell and PRP bank through their cryopreservation services, Vetherapy ensures that these therapeutic products are readily available for immediate use, addressing various clinical needs for animal patients.
Antibiotic Adjuvant, Inc. develops decision support software aimed at enhancing antibiotic use in healthcare settings. Its primary product, SmartSteward, is designed to monitor and reduce infections and antibiotic resistance within healthcare facilities. The software serves various healthcare professionals by equipping administrators with tools and educational resources to optimize antibiotic use, providing physicians with relevant prescribing information, and supplying nurses with surveillance tools for infection reporting and diagnosis. Founded in 2014 and based in Gainesville, Florida, Antibiotic Adjuvant is unique in its approach, targeting 90% of physician hospital antibiotic prescriptions and facilitating automated resistance control to streamline antibiotic usage patterns.
MezoMax, Inc. is a biotechnology company established in 2017 and headquartered in San Francisco, California. The company specializes in oral therapies designed to repair nonhealing fractures and promote strong bones. MezoMax's innovative approach includes a novel calcium gluconate stereoisomer that enhances the healing of bone fractures, improves osteoporosis treatment, and supports overall bone health, particularly in elderly patients. By focusing on the restoration of bone tissue and the treatment of various bone diseases, MezoMax aims to address significant challenges in bone health and recovery.
sRNAlytics developed a computational platform to diagnose and subtype disease using small RNAs. We offer our technology and services to drug developers to identify companion diagnostics and uncover new therapeutic targets.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.
BioAesthetics Corporation, founded in 2015 as a spin-out from Tulane University, specializes in developing innovative reconstruction solutions for breast cancer patients who have undergone mastectomies. The company's primary product is a tissue-engineered nipple-areolar complex (NAC), designed to facilitate the regeneration of the nipple and areola during the breast reconstruction phase. This biologically derived graft serves as an acellular, off-the-shelf option for plastic and reconstructive surgeons, allowing the patient's own cells to integrate and restore the NAC. Currently in the pre-clinical phase, this patent-pending technology aims to improve surgical outcomes and enhance the quality of life for patients with incomplete or removed NACs due to disease, surgery, or birth defects. BioAesthetics is headquartered in Research Triangle Park, North Carolina.
Stelvio Oncology, founded in 2017 and based in San Francisco, California, specializes in developing therapeutics for glioblastoma, an aggressive form of brain cancer. The company focuses on converting glioblastoma multiforme tumor cells into healthy cells by leveraging unique epigenetic signatures associated with specific cell types. Stelvio employs advanced technologies, including microscopic imaging of epigenetic landscapes, to identify small molecules that can induce differentiation or reverse cancerous cells into benign states. This personalized approach aims to provide innovative treatment options for glioblastoma patients, combining scientific creativity with clinical expertise to advance drug therapies and precision medicine diagnostics.
Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.
AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.
NeuroQore, Inc. is a Canadian company based in Ottawa, established in 2012, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating resistant cases of depression. The organization is composed of a dedicated team of scientists, engineers, and clinicians who focus on pioneering neuromodulation treatments for various neurobehavioral conditions. NeuroQore collaborates with leading universities and research clinics to explore innovative solutions for major depressive disorder and suicidality, striving to improve the lives of individuals affected by these serious mental health issues. The company's advanced technology is designed for deployment in healthcare facilities globally.
AnimalBiome focuses on improving the gut health of dogs and cats in the United States that suffer from chronic digestive disorders. The company offers microbiome-based supplements and non-invasive diagnostic tools designed to identify imbalances in the gut microbiome. Utilizing deoxyribonucleic acid sequencing, AnimalBiome's diagnostic services assess the balance of gut bacteria, allowing pet owners to gain insights into their pets' gut health. This information enables tailored supplementation aimed at restoring gut balance, ultimately promoting a healthier and happier life for pets.
Vali Nanomedical Corporation, a biotechnology company, develops a multidrug-delivery platform technology using proprietary nanoparticles that have multilayered structures. It offers cross-linked multilamellar liposome nanoparticle technology that allows a nano-delivery of multiple chemical payloads in defined ratios to tumors. The company was founded in 2013 and is based in Los Angeles, California.
NeuroQore, Inc. is a Canadian company based in Ottawa, established in 2012, specializing in the development of a monophasic repetitive transcranial magnetic stimulation system aimed at treating resistant cases of depression. The organization is composed of a dedicated team of scientists, engineers, and clinicians who focus on pioneering neuromodulation treatments for various neurobehavioral conditions. NeuroQore collaborates with leading universities and research clinics to explore innovative solutions for major depressive disorder and suicidality, striving to improve the lives of individuals affected by these serious mental health issues. The company's advanced technology is designed for deployment in healthcare facilities globally.
Mendel.ai develops artificial intelligence-based solutions aimed at enhancing clinical oncology research and improving patient care. Founded in 2005 and headquartered in San Jose, California, the company offers a range of software solutions that address various challenges in the clinical trial process. Its products include Read, which provides instant data abstraction; Retina, designed to minimize data loss during optical character recognition; Redact, which addresses privacy concerns in patient record sharing; Research, a clinical search engine; Recruit, facilitating patient prescreening and enrollment; and Enrich, which offers real-time access to real-world data from leading oncology clinics. By transforming unstructured electronic medical records and clinical literature into analytics-ready data, Mendel.ai aims to streamline global oncology research and automate clinical trials.
Qidni Labs Inc., based in Kitchener, Canada, focuses on developing innovative renal replacement therapies for individuals suffering from End Stage Renal Disease (ESRD). With over two million patients globally facing this condition, the demand for effective treatment options is significant. Currently, patients rely on dialysis as a critical interim solution while awaiting kidney transplants, yet the survival rate for those on dialysis falls below 40% within five years. Furthermore, the financial burden of dialysis can exceed $60,000 annually in Canada and the United States, in addition to the physical and emotional challenges patients endure due to complications and lifestyle limitations. Qidni Labs aims to address these pressing issues by advancing therapies that could improve treatment outcomes and enhance the quality of life for those affected by ESRD.
MFluidX, Inc. is a diagnostic company based in Berkeley, California, that specializes in developing innovative microfluidic chips for the rapid detection of infectious diseases. Incorporated in 2015, the company has designed a portable DNA diagnostic test that is compact, roughly the size of a stick of gum, and capable of delivering results in just thirty minutes. This self-powered, disposable chip offers a cost-effective alternative to traditional bulky lab diagnostics, costing significantly less while maintaining high sensitivity through nucleic acid amplification. MFluidX focuses on addressing the urgent need for quickly deployable diagnostics in response to outbreaks of diseases such as Zika and Dengue, thereby enhancing the ability of healthcare providers to diagnose and manage infectious disease threats effectively.
Orphidia Ltd is focused on developing a portable blood diagnostic platform that enables rapid laboratory testing. The company has created a device capable of conducting 40 common blood tests from a single drop of blood, delivering results in just 20 minutes. Incorporated in 2013 and headquartered in London, United Kingdom, Orphidia aims to enhance patient care by making laboratory tests more accessible and efficient.
Aluna is a healthcare company based in San Francisco, California, that specializes in respiratory management solutions for individuals with chronic lung conditions, including asthma, cystic fibrosis, and COPD. The company has developed a portable spirometry test device that is integrated with an interactive iPhone game, creating an engaging way for users to monitor their respiratory health. Aluna's health platform enables users, particularly children and their parents, to track asthma symptoms, manage medication, and monitor treatment progress. Additionally, the platform offers real-time data that can be shared with healthcare providers, facilitating better insights into asthma triggers and events. Founded in 2013, Aluna aims to improve the quality of life for those living with chronic respiratory conditions.
Developer of invitro diagnostics technology designed for accurate and accessible testing products. The company's platform utilizes novel technologies to create mobile, point-of-care, and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing, enabling people to put healthcare information directly into their hands to improve their quality of life.
Vali Nanomedical Corporation, a biotechnology company, develops a multidrug-delivery platform technology using proprietary nanoparticles that have multilayered structures. It offers cross-linked multilamellar liposome nanoparticle technology that allows a nano-delivery of multiple chemical payloads in defined ratios to tumors. The company was founded in 2013 and is based in Los Angeles, California.
V-Sense Medical specializes in the development of remote medical monitoring devices that utilize advanced radar technology to monitor vital signs without direct contact with patients. By eliminating the need for traditional instruments such as wires, electrodes, and blood pressure cuffs, V-Sense Medical addresses significant challenges in medical facilities, including patient safety and comfort, measurement accuracy, and the efficiency of healthcare delivery. Their innovative approach allows for continuous monitoring of critical health metrics like heart rate and respiratory rate, providing healthcare professionals with real-time insights and alerts regarding patient health. This technology not only enhances the precision of medical assessments but also streamlines workflows, ultimately facilitating quicker and more effective patient care in urgent medical environments.
MYi Diagnostics & Discovery, Inc. is a biomedical research company based in San Diego, California, that specializes in the development of diagnostic assays for longitudinal profiling of blood and other tissues. Founded in 2015, the company focuses on multiplexed proteomic profiling to improve precision medicine. Its innovative technology aims to replace traditional diagnostics for various conditions, including cancers, infectious diseases, and metabolic disorders, by providing multi-analyte assays with single-cell sensitivity. This approach enables healthcare providers to identify unique biomarkers in patient biopsies and generates actionable individualized information, ultimately streamlining clinical intervention strategies for both healthy and disease-predisposed individuals.
Orphidia Ltd is focused on developing a portable blood diagnostic platform that enables rapid laboratory testing. The company has created a device capable of conducting 40 common blood tests from a single drop of blood, delivering results in just 20 minutes. Incorporated in 2013 and headquartered in London, United Kingdom, Orphidia aims to enhance patient care by making laboratory tests more accessible and efficient.
Orphidia Ltd is focused on developing a portable blood diagnostic platform that enables rapid laboratory testing. The company has created a device capable of conducting 40 common blood tests from a single drop of blood, delivering results in just 20 minutes. Incorporated in 2013 and headquartered in London, United Kingdom, Orphidia aims to enhance patient care by making laboratory tests more accessible and efficient.
BlueTurtleBio Technologies creates a next generation therapeutic using a patent pending platform technology. The company's mission is the golden triangle of healthcare: safety, effectiveness and affordability. Most healthcare options miss one or more of these standards. At Blue Turtle, they plan to recruit a genetically malleable and easily replenishable organ in the human body: the microbiome.
Extem Bioscience Corp., located in Burnaby, Canada, specializes in isolating and expanding mesenchymal stem cells (MSCs) to supply researchers with ready-to-use adult stem cells. The company's methodology ensures the production of consistent and reliable MSCs, aiming to advance the field of stem cell research. Extem's team of scientists and engineers is dedicated to exploring the potential of MSCs as a therapeutic solution for various conditions, including injuries like torn menisci and fractured bones. By focusing on the development of biomaterials that may offer permanent and functional solutions, Extem seeks to enhance the quality of life for patients facing debilitating health issues.
Extem Bioscience Corp., located in Burnaby, Canada, specializes in isolating and expanding mesenchymal stem cells (MSCs) to supply researchers with ready-to-use adult stem cells. The company's methodology ensures the production of consistent and reliable MSCs, aiming to advance the field of stem cell research. Extem's team of scientists and engineers is dedicated to exploring the potential of MSCs as a therapeutic solution for various conditions, including injuries like torn menisci and fractured bones. By focusing on the development of biomaterials that may offer permanent and functional solutions, Extem seeks to enhance the quality of life for patients facing debilitating health issues.
Developer of invitro diagnostics technology designed for accurate and accessible testing products. The company's platform utilizes novel technologies to create mobile, point-of-care, and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing, enabling people to put healthcare information directly into their hands to improve their quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.